<DOC>
	<DOCNO>NCT02171533</DOCNO>
	<brief_summary>To investigate whether extent P-glycoprotein inhibitor ( P-gp ) verapamil affect pharmacokinetic parameter dabigatran verapamil give different dosage , different formulation ( immediate release ( IR ) extend release ( ER ) ) , different interval relation dabigatran dose .</brief_summary>
	<brief_title>Relative Bioavailability Single Oral Doses Dabigatran Etexilate With Without Oral Administration Verapamil Two Different Dosages Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test 2 . Age ≥18 ≤55 year 3 . Body mass index ( BMI ) ≥18.5 BMI ≤29.9 kg/m2 4 . Signed date write informed consent prior admission study accordance GCP local legislation Exclusion criterion : 1 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . Relevant surgery gastrointestinal tract 3 . History bleed disorder acute blood coagulation defect 4 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 5 . History relevant orthostatic hypotension , faint spell blackouts 6 . Chronic relevant acute infection 7 . History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator 8 . Pulse rate 50 bpm systolic blood pressure &lt; 90 mm Hg screening . ECG : PR &gt; 170 m ( Part 1 ) , AV block ≥1st degree ( Part 2 ) screen 9 . Use drug might reasonably influence result trial base knowledge time protocol preparation within four week prior administration trial , especially intake medication , influence blood clotting , i.e. , acetylsalicylic acid , cumarin etc . 10 . Participation another trial investigational drug within two month prior administration trial 11 . Smoker ( 15 cigarette 3 cigar 3 pipe per day ) 12 . Alcohol abuse ( 60 g/day men 40 g/day woman ) 13 . Drug abuse 14 . Blood donation ( 100 mL within four week prior administration trial ) 15 . Excessive physical activity ( within one week prior administration trial ) 16 . Any laboratory value outside reference range clinical relevance 17 . Planned surgery within four week follow endof study examination 18 . The subject able understand comply protocol requirement , instruction , protocolstated restriction dietary regimen study centre For male subject : 19 . Male subject agree minimise risk female partner become pregnant first dose day 3 month completion post study medical . Acceptable method contraception comprise barrier contraception medically accept contraceptive method female partner ( intrauterine device spermicide , hormonal contraceptive since least two month ) For female subject : 20 . Pregnancy / positive pregnancy test , plan become pregnant study within 1 month study completion 21 . No adequate contraception study 1 month study completion , i.e . implant , injectables , combine oral contraceptive , IUD ( intrauterine device ) , sexual abstinence ( least 1 month prior enrolment ) , vasectomised partner ( vasectomy perform least 1 year prior enrolment ) , surgical sterilisation ( incl . hysterectomy ) . Females , vasectomise partner , sexually abstinent surgically sterile ask additionally use barrier contraception method ( e.g . condom , diaphragm spermicide ) 22 . Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>